High dose mitomycin C for treatment of advanced gastric cancer.
Thirty five patients (26 males and 9 females) with advanced gastric cancer confirmed by pathology were treated by high-dose mitomycin C. According to the following dose and schedules: Mitomycin C 20 mg intravenously per week and a total of 60 mg. Three weeks later, all the patients received FT-207 600 mg daily and a total of 20-40 g. The ages ranged from 24 to 75 years, 11 had cancer of cardia, 6 had cancer of gastric body, and 18 had cancer of gastric antrum. Eleven patients could not have an operation. Seventeen patients were recurrence of post operation. Eighteen of 35 patients received CR (7/35) and PR (11/35), the response rate was 51.43% of the responders, the median duration of remission and survival were 7.3 (range, 2-16) and 12.2 (range, 3-30) months, respectively. Common doses were instilled. The main side effects were leukopenia (10/35) and thrombocytopenia (7/35). None of these patients had liver and kidney function damage.
Jin
M L
ML
Department of Gastric Diseases Research, Beijing Institute for Cancer Research, P.R. China.
Yang
B Q
BQ
Zhang
W
W
Ren
P
P
D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D002299:Cardia; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D011706:Pyloric Antrum; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage
D005641:Tegafur; D016685:Mitomycin